Realbotix Secures Merger Lifeline from Onconetix in High-Stakes AI Pivot

LAS VEGAS, NV – September 14, 2026 – In the high-stakes world of corporate mergers, seemingly minor financial arrangements often tell the most significant stories. Such is the case with Realbotix LLC, the humanoid robotics subsidiary of Realbotix Corp., which has just secured a bridge loan facility of up to $5 million from its proposed merger partner, Onconetix, Inc. On the surface, it’s a standard move to provide working capital during a transitional period. But dig deeper, and this loan reveals itself as the critical linchpin holding together a bold, unorthodox, and potentially transformative deal.

This isn't merely about keeping the lights on. The terms of this loan signal a profound commitment from Onconetix, a struggling biotech firm, to pivot its entire corporate identity towards the burgeoning field of artificial intelligence. For Realbotix, it’s the necessary fuel to cross the finish line of a transaction that promises access to the coveted Nasdaq exchange and the U.S. capital markets essential for scaling its ambitious vision. This agreement is less a simple loan and more a surgically placed suture, binding the fates of two disparate companies as they navigate a complex corporate restructuring.

The Anatomy of a Strategic Loan

To understand the gravity of this deal, one must look past the headline figure and into the structure of the promissory note. This is no ordinary debt instrument. Onconetix, the lender, has extended the capital to Realbotix LLC on a non-interest-bearing basis. The entire principal, starting with an initial draw of $2.5 million, will be automatically cancelled and discharged upon the successful closing of the merger. In essence, it’s a grant, contingent on the deal's completion.

This single term speaks volumes. Onconetix is not acting as a traditional lender seeking a return on capital; it is acting as a strategic partner investing in the health of its future asset. By forgoing interest, Onconetix ensures that Realbotix is not burdened with additional liabilities that could complicate the merger or drain its resources. As Realbotix CEO Andrew Kiguel stated, “The loan provides working capital for Realbotix LLC during the merger process, and preserves the economic alignment between Realbotix and Onconetix.”

However, this alignment comes with a formidable safeguard. Should the merger agreement terminate for any reason, the loan immediately converts into a standard debt obligation, with interest accruing at a steep 12% per annum from the date of termination. This clause serves as a powerful incentive for Realbotix to see the merger through, effectively creating a financial penalty for walking away. For Onconetix, it mitigates the risk of its capital being used to simply tide Realbotix over, only for the acquisition to fail.

Furthermore, a negative covenant restricts Realbotix and its parent corporation from incurring any additional debt without Onconetix's prior written consent. This gives Onconetix a crucial element of control over its target's financial discipline during this sensitive period, preventing any unforeseen liabilities from emerging that could devalue the company it is poised to acquire. The loan, therefore, is a masterclass in M&A strategy: it provides vital support while simultaneously binding the recipient and protecting the provider.

A Tale of Two Companies: The Merger Imperative

The necessity of this strategically crafted loan becomes crystal clear when examining the contrasting positions of the two firms. Realbotix Corp. operates at the cutting edge of humanoid robotics, a field demanding immense and continuous capital investment. While the parent company reported a debt-free balance sheet and a healthy cash position of over $8 million earlier this year, its financials also show the strains of innovation, with recent quarterly revenues declining year-over-year. The specific subsidiary, Realbotix LLC, is ramping up, with recent revenue growth attributed to its first robot deliveries. This bridge loan is precisely for this entity, suggesting a targeted need for capital to scale production and maintain momentum as the larger corporate structure is rearranged.

The merger itself is the ultimate prize for Realbotix. The transaction is structured as a reverse merger that will give Realbotix Corp. a commanding 75% to 90% ownership of the new combined entity, which is slated to trade on Nasdaq. This move is a strategic masterstroke to sidestep a lengthy IPO process and gain immediate access to the deep pools of U.S. institutional capital—a non-negotiable for any firm with ambitions to compete in the global AI and robotics race.

On the other side of the table sits Onconetix, a commercial-stage biotech company whose future looks far less certain. Formerly known as Blue Water Biotech, the company has been plagued by significant losses, negative cash flow, and a dwindling cash reserve. Its own financial filings from mid-2026 raised “substantial doubt” about its ability to continue as a going concern. For Onconetix, this merger is not just a strategic pivot; it is an act of corporate survival. By acquiring Realbotix LLC, Onconetix is attempting to shed its struggling biotech skin and reincarnate itself as a player in one of the world's most dynamic growth sectors.

Onconetix's High-Stakes Bet on an Embodied Future

The move by Onconetix represents one of the most dramatic strategic shifts in recent memory. It is abandoning its core competency in therapeutics and diagnostics to wager its entire future on humanoid robotics. The rationale lies in the staggering market projections for the sector. Analysts forecast the humanoid robot market, valued at just over $2 billion in 2025, to explode to over $40 billion by 2035. This exponential growth curve offers a tantalizing path to value creation that its previous biotech ventures could not.

In Realbotix, Onconetix has found a compelling target. Realbotix isn't just building mechanical workers; its patented technology focuses on embodied AI capable of lifelike facial expressions and advanced social engagement. This positions its platforms for high-value applications in healthcare, education, and service industries, not just industrial automation. By providing the bridge loan, Onconetix is doing more than just facilitating a merger—it is making a down payment on this new identity and ensuring its ticket into this high-growth future remains viable.

The loan is a calculated risk to keep the target company healthy and on track while Onconetix orchestrates its own profound transformation. It is a tacit admission that Realbotix's technology and market position are valuable enough to justify funding its operations even before the acquisition is finalized. This financial commitment demonstrates to Onconetix's own shareholders that management is serious about this radical new direction, even as it asks for their approval to proceed.

The path forward is still fraught with risk. The merger requires shareholder and regulatory approvals, and integrating two companies from vastly different industries is a monumental task. But this unsecured bridge loan, with its clever blend of support and security, has undeniably strengthened the bond between the two firms. It is the financial glue that holds this ambitious vision together, a clear signal that both parties are now economically and strategically locked on a shared course toward creating a new force in the world of artificial intelligence.